ClinicalTrials.gg
CompletedNCT04840485Updated May 22, 2024

Efficacy and Safety of SHR-1314 in Patients With Active Ankylosing Spondylitis

A Phase 2/3 interventional study of SHR-1314 and SHR-1314 in Ankylosing Spondylitis, sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-22.

Sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
548
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 76 studies in Spondylitis, Ankylosing with a site in China — 19 open to participants now, 22 under way, 4 of them phase 3. Spondylitis, Ankylosing · China.

Enrollment
4th of 62
548 · median 150
Started
2021
with 7 others
Phase 2/3
4 of 76
none open now
Registered
39th of 76
by date

Among the 76 studies in Spondylitis, Ankylosing with a site in China, this one is the 4th largest by enrollment of the 62 interventional ones that give a count, is one of 8 that started in 2021, is one of 4 in phase 2/3, and was the 39th registered.

Spondylitis, Ankylosing

533 studies on the registry are indexed under Spondylitis, Ankylosing; 99 are open to participants now.

Browse Spondylitis, Ankylosing studies →

Open to participants now

19 of the 76 studies in Spondylitis, Ankylosing with a site in China are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 63 Spondylitis, Ankylosing studies recruiting now, 25 (40%) set no upper age limit and 32 (51%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Spondylitis, Ankylosing with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to assess efficacy, safety, pharmacokinetics and immunogenicity of subcutaneous SHR-1314 in patients with active ankylosing spondylitis

03

Conditions studied

  • Ankylosing Spondylitis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Active Ankylosing Spondylitis, prior radiographic evidence according to the Modified NY Criteria (1984), inadequate response, or intolerance to NSAIDs

Exclusion criteria

Exclusion Criteria:

  • pregnancy or lactation, serious infectious, , previous exposure to any biological agent excluding TNF antagonists
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
548 participants (actual)

Study arms

  • Experimental
    Treatment group A

    Drug: SHR-1314

  • Experimental
    Treatment group B

    Drug: SHR-1314

  • Placebo comparator
    Treatment group C

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Responded for Assessment of SpondyloArthritis international Society 20 Criteria (ASAS20) at 16 Weeks

    Time frame: 16 Weeks

Secondary outcomes

  1. Percentage of Participants Responded for ASAS 20 Response at 32 Weeks

    Time frame: 32 Weeks

  2. Percentage of Participants Responded for ASAS 40 Response at 16 and 32 Weeks

    Time frame: 16 and 32 Weeks

  3. Percentage of Participants Responded for ASAS 5/6 Response at 16 and 32 Weeks

    Time frame: 16 and 32 Weeks

  4. Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at 16 and 32 Weeks

    Time frame: 16 and 32 Weeks

  5. Change From Baseline in Ankylosing Spondylitis Quality of Life Questionnaire (ASQoL) at 16 and 32 Weeks

    Time frame: 16 and 32 Weeks

07

Study locations

1 site
  • Chinese PLA General Hospital
    Beijing, Beijing 100853, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2021 to primary completion in Nov 2023, 28 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2021
First posted
Apr 12, 2021
StartActual
Jun 9, 2021
Primary completionActual
Nov 3, 2023
CompletionActual
Feb 28, 2024
Last update
May 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04840485
Responsible party
Sponsor
First posted
Apr 12, 2021
Start date
Jun 9, 2021
Primary completion
Nov 3, 2023
Completion
Feb 28, 2024
Last update
May 22, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vunakizumab

Start the discussion